United Nations/Geneva: The technical advisory group of the World Health Organisation (WHO) sought “additional clarifications” from Bharat Biotech on Tuesday for its COVID-19 vaccine Covaxin to conduct a final “risk-benefit assessment” for the vaccine’s Emergency Use Listing.
The WHO technical advisory group will again meet on November 3 for a final assessment.
Covaxin manufacturer Hyderabad-based Bharat Biotech had submitted EOI (Expression of Interest) to the WHO on April 19 for the vaccine’s Emergency Use Listing (EUL).
The technical advisory group met on Tuesday to review data on Covaxin for the emergency use listing.
“The TAG met today (26 October 2021) and decided that additional clarifications from the manufacturer are needed to conduct a final EUL risk-benefit assessment for global use of the vaccine,” the WHO was quoted as saying by news agency PTI.
“The TAG expects to receive these clarifications from the manufacturer by the end of this week, and aims to reconvene for the final risk-benefit assessment on Wednesday, 3 November,” WHO added.
Update: The @WHO independent TAG met today & asked for addnl clarifications from the manufacturer @BharatBiotech to conduct a final EUL risk-benefit assessment for global use of #Covaxin. It will reconvene for the final assessment on Wednesday, 3 November if data received soon
— Soumya Swaminathan (@doctorsoumya) October 26, 2021
ALSO READ: Will WHO Finally Approve Covaxin Today?
